These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 30814111)

  • 21. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.
    Lubieniecka JM; de Bruijn DR; Su L; van Dijk AH; Subramanian S; van de Rijn M; Poulin N; van Kessel AG; Nielsen TO
    Cancer Res; 2008 Jun; 68(11):4303-10. PubMed ID: 18519690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics.
    Su L; Sampaio AV; Jones KB; Pacheco M; Goytain A; Lin S; Poulin N; Yi L; Rossi FM; Kast J; Capecchi MR; Underhill TM; Nielsen TO
    Cancer Cell; 2012 Mar; 21(3):333-47. PubMed ID: 22439931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frequent TRPS1 expression in synovial sarcoma is associated with SS18-SSX fusion oncoprotein activity.
    Cloutier JM; Ingram DR; Wani K; Lazar AJ; Wang WL
    Hum Pathol; 2022 Dec; 130():88-94. PubMed ID: 36162599
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Downregulation of SS18-SSX1 expression in synovial sarcoma by small interfering RNA enhances the focal adhesion pathway and inhibits anchorage-independent growth in vitro and tumor growth in vivo.
    Takenaka S; Naka N; Araki N; Hashimoto N; Ueda T; Yoshioka K; Yoshikawa H; Itoh K
    Int J Oncol; 2010 Apr; 36(4):823-31. PubMed ID: 20198325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase transition and remodeling complex assembly are important for SS18-SSX oncogenic activity in synovial sarcomas.
    Cheng Y; Shen Z; Gao Y; Chen F; Xu H; Mo Q; Chu X; Peng CL; McKenzie TT; Palacios BE; Hu J; Zhou H; Long J
    Nat Commun; 2022 May; 13(1):2724. PubMed ID: 35585082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Verteporfin targeting YAP1/TAZ-TEAD transcriptional activity inhibits the tumorigenic properties of gastric cancer stem cells.
    Giraud J; Molina-Castro S; Seeneevassen L; Sifré E; Izotte J; Tiffon C; Staedel C; Boeuf H; Fernandez S; Barthelemy P; Megraud F; Lehours P; Dubus P; Varon C
    Int J Cancer; 2020 Apr; 146(8):2255-2267. PubMed ID: 31489619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular detection of SS18-SSX fusion gene transcripts by cRNA in situ hybridization in synovial sarcoma using formalin-fixed, paraffin-embedded tumor tissue specimens.
    Kanemitsu S; Hisaoka M; Shimajiri S; Matsuyama A; Hashimoto H
    Diagn Mol Pathol; 2007 Mar; 16(1):9-17. PubMed ID: 17471153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The C terminus of the synovial sarcoma-associated SSX proteins interacts with the LIM homeobox protein LHX4.
    de Bruijn DR; van Dijk AH; Willemse MP; van Kessel AG
    Oncogene; 2008 Jan; 27(5):653-62. PubMed ID: 17667940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SS18-SSX-regulated miR-17 promotes tumor growth of synovial sarcoma by inhibiting p21WAF1/CIP1.
    Minami Y; Kohsaka S; Tsuda M; Yachi K; Hatori N; Tanino M; Kimura T; Nishihara H; Minami A; Iwasaki N; Tanaka S
    Cancer Sci; 2014 Sep; 105(9):1152-9. PubMed ID: 24989082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Role for SMARCB1 in Synovial Sarcomagenesis Reveals That SS18-SSX Induces Canonical BAF Destruction.
    Li J; Mulvihill TS; Li L; Barrott JJ; Nelson ML; Wagner L; Lock IC; Pozner A; Lambert SL; Ozenberger BB; Ward MB; Grossmann AH; Liu T; Banito A; Cairns BR; Jones KB
    Cancer Discov; 2021 Oct; 11(10):2620-2637. PubMed ID: 34078620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinical implication of SS18-SSX fusion gene in synovial sarcoma.
    Ren T; Lu Q; Guo W; Lou Z; Peng X; Jiao G; Sun Y
    Br J Cancer; 2013 Oct; 109(8):2279-85. PubMed ID: 24022186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma.
    Brien GL; Remillard D; Shi J; Hemming ML; Chabon J; Wynne K; Dillon ET; Cagney G; Van Mierlo G; Baltissen MP; Vermeulen M; Qi J; Fröhling S; Gray NS; Bradner JE; Vakoc CR; Armstrong SA
    Elife; 2018 Nov; 7():. PubMed ID: 30431433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The synovial-sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation.
    de Bruijn DR; Allander SV; van Dijk AH; Willemse MP; Thijssen J; van Groningen JJ; Meltzer PS; van Kessel AG
    Cancer Res; 2006 Oct; 66(19):9474-82. PubMed ID: 17018603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of SHCBP1 as a novel downstream target gene of SS18-SSX1 and its functional analysis in progression of synovial sarcoma.
    Peng C; Zhao H; Chen W; Song Y; Wang X; Li J; Qiao Y; Wu D; Ma S; Wang X; Gao C
    Oncotarget; 2016 Oct; 7(41):66822-66834. PubMed ID: 27572315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synovial sarcoma is a stem cell malignancy.
    Naka N; Takenaka S; Araki N; Miwa T; Hashimoto N; Yoshioka K; Joyama S; Hamada K; Tsukamoto Y; Tomita Y; Ueda T; Yoshikawa H; Itoh K
    Stem Cells; 2010 Jul; 28(7):1119-31. PubMed ID: 20518020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TAZ and YAP are frequently activated oncoproteins in sarcomas.
    Fullenkamp CA; Hall SL; Jaber OI; Pakalniskis BL; Savage EC; Savage JM; Ofori-Amanfo GK; Lambertz AM; Ivins SD; Stipp CS; Miller BJ; Milhem MM; Tanas MR
    Oncotarget; 2016 May; 7(21):30094-108. PubMed ID: 27129148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma.
    Trautmann M; Menzel J; Bertling C; Cyra M; Isfort I; Steinestel K; Elges S; Grünewald I; Altvater B; Rossig C; Fröhling S; Hafner S; Simmet T; Åman P; Wardelmann E; Huss S; Hartmann W
    Clin Cancer Res; 2017 Oct; 23(20):6227-6238. PubMed ID: 28637688
    [No Abstract]   [Full Text] [Related]  

  • 38. Identification of novel SSX1 fusions in synovial sarcoma.
    Yoshida A; Arai Y; Satomi K; Kubo T; Ryo E; Matsushita Y; Hama N; Sudo K; Komiyama M; Yatabe Y; Shibata T; Ichikawa H; Ichimura K; Kawai A; Mori T
    Mod Pathol; 2022 Feb; 35(2):228-239. PubMed ID: 34504309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma.
    Baranov E; McBride MJ; Bellizzi AM; Ligon AH; Fletcher CDM; Kadoch C; Hornick JL
    Am J Surg Pathol; 2020 Jul; 44(7):922-933. PubMed ID: 32141887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TAZ-CAMTA1 and YAP-TFE3 alter the TAZ/YAP transcriptome by recruiting the ATAC histone acetyltransferase complex.
    Merritt N; Garcia K; Rajendran D; Lin ZY; Zhang X; Mitchell KA; Borcherding N; Fullenkamp C; Chimenti MS; Gingras AC; Harvey KF; Tanas MR
    Elife; 2021 Apr; 10():. PubMed ID: 33913810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.